What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
Tempest Therapeutics股票（纳斯达克股票代码：TPST）周四交易下跌，交易量为2100万股，数据来自Benzinga Pro。
The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).
该公司宣布了有关amezalpat2（TPST-1120）进行中的1b/2期临床研究的新数据。
The drug candidate delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
与单独使用atezolizumab和bevacizumab相比，在无法手术切除或转移的肝细胞癌（HCC，最常见的原发性肝癌类型）的一线治疗中，该药物候选组合物与atezolizumab和bevacizumab相结合，可使中位总体生存优势提高六个月。
At the cutoff date of February 14, 2024, the new data from 40 patients randomized to the amezalpat arm and 30 patients randomized to the control arm show:
截至2024年2月14日，amezalpat组随机分配的40名患者和对照组随机分配的30名患者的新数据显示：
- 21-month median OS for the amezalpat arm versus 15 months for the control arm, a six-month survival advantage.
- 20/40 patients remain in survival follow-up in the amezalpat arm, compared to 9/30 patients in the control arm.
- 0.65 hazard ratio for OS, revealing a stable HR since the top-line analysis 10 months earlier when the HR was 0.59.
- A manageable safety profile is consistent with Phase 1 data.
- amezalpat组的中位OS为21个月，对照组为15个月，优势为六个月。
- amezalpat组中有20/40名患者进行生存随访，对照组中有9/30名患者进行生存随访。
- OS的危险度比为0.65，比头条分析时10个月前的0.59相对稳定。
- 可管理的安全性与1期数据一致。
The earlier top-line data analysis, dated April 20, 2023, had a median follow-up of 9.2 and 9.9 months for the amezalpat and control arms, respectively and showed:
早期头条数据分析于2023年4月20日，amezalpat组和对照组的中位随访时间分别为9.2个月和9.9个月，并显示：
- A confirmed objective response rate of 30% for the amezalpat arm versus 13.3% for the control arm.
- Biomarker subpopulation findings were consistent with the mechanism of action of amezalpat. Patients with b-catenin activating mutations (21% in this study (n=7)) showed a cORR of 43% and a disease control rate (DCR) of 100% in the amezalpat arm.
- The amezalpat arm was consistently active across both PD-L1 positive and PD-L1 negative tumors, with a cORR of 27% in the amezalpat arm compared to 7% for the control arm in PD-L1 negative tumors.
- amezalpat组的经确认的客观反应率为30％，对照组为13.3％。
- 生物标志物亚人群发现与amezalpat的作用机制一致。该研究中具有β-catenin激活突变（占全部研究的21％（n = 7））的患者，在amezalpat组中的完全缓解率为43％，疾病控制率为100％。
- 无论PD-L1阳性还是PD-L1阴性肿瘤，amezalpat组都保持了一致的活性，在PD-L1阴性肿瘤中，amezalpat组的客观缓解率为27％，而对照组为7％。
Amezalpat remains well tolerated, with safety data comparable between the two arms.
Amezalpat仍然耐受良好，两组之间的安全数据相当。
HCC is an aggressive cancer with rising mortality and is projected to become the third leading cause of cancer death by 2030. Every year, more than 900,000 people worldwide are diagnosed with HCC.
HCC是一种具有不断上升的死亡率的侵袭性肿瘤，并且预计将成为2030年第三大癌症死亡原因。每年有超过900,000人被诊断患有HCC。
Price Action: TPST shares are down 16.5% at $2.38 before spiking as high as $4.82 during the premarket session at last check Thursday.
价格走势：截至周四最后一次查询，TPST股价下跌16.5％，报2.38美元，并在盘前交易中最高飙升至4.82美元。
Image by PDPics from Pixabay
来自Pixabay的PDPics图片